Knight Therapeutics Inc. (TSX: GUD) announced it has fully repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company originally drew $60 million from the facility in June 2025 to finance its acquisition of Paladin, a strategic move to expand its pharmaceutical footprint in the Americas.
The repayment was funded through robust cash flow generated by Knight’s operations in Canada and Latin America, underscoring the company’s financial health and operational efficiency. Despite the repayment, the revolving credit facility remains available, providing borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature subject to certain conditions. This liquidity supports Knight’s ongoing growth strategy across its pan-American pharmaceutical business.
This development is significant for investors and the pharmaceutical sector as it demonstrates Knight’s ability to generate sufficient internal cash flow to retire debt swiftly, reducing interest expenses and strengthening its balance sheet. The Paladin acquisition, completed earlier this year, was a key milestone in Knight’s expansion strategy, and the rapid repayment signals successful integration and operational performance.
Knight Therapeutics, headquartered in Montreal, Canada, focuses on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM. The company’s shares trade on the TSX under the symbol GUD. For more information about the company, please visit www.knighttx.com. The full press release is available at https://ibn.fm/8eluB.
